{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T04:05:50Z","timestamp":1750997150405},"reference-count":70,"publisher":"Bentham Science Publishers Ltd.","issue":"2","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CRP"],"published-print":{"date-parts":[[2019,7,16]]},"abstract":"<jats:sec><jats:title>Background:<\/jats:title><jats:p>Pancreatic Neuroendocrine Tumors (PNETs) are rare neoplasms, sporadic or familial, even being part of a syndrome. Their diagnosis is based on symptoms, hormonal disorders or may be fortuitous. The role of Nuclear Medicine is important, mainly because of the possibility of a theranostic strategy. This approach is allowed by the availability of biochemical agents, which may be labeled with radionuclides suitable for diagnostic or therapeutic purposes, showing almost identical pharmacokinetics. The major role for radiopharmaceuticals is connected with radiolabeled Somatostatin Analogues (SSA), since somatostatin receptors are highly expressed on some of the neoplastic cell types.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion:<\/jats:title><jats:p>Nowadays, in the category of radiolabeled SSA, although 111In-pentetreotide, firstly commercially proposed, is still used, the best choice for diagnosis is related to the so called DOTAPET radiotracers labeled with 68-Gallium (Ga), such as 68Ga-DOTATATE, 68Ga-DOTANOC, and 68Ga-DOTATOC. More recently, labeling with 64-Copper (Cu) (64Cu-DOTATATE) has also been proposed. In this review, we discuss the clinical interest of a SAA (Tektrotyd\u00a9) radiolabeled with 99mTc, a gamma emitter with better characteristics, with respect to 111Indium, radiolabeling Octreoscan \u00a9. By comparing both pharmacokinetics and pharmacodynamics of Octreoscan\u00a9, Tektrotyd\u00a9 and PET DOTA-peptides, on the basis of literature data and of our own experience, we tried to highlight these topics to stimulate further studies, individuating actual clinical indications for all of these radiotracers.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion:<\/jats:title><jats:p>In our opinion, Tektrotyd\u00a9 could already find its applicative dimension in the daily practice of NETs, either pancreatic or not, at least in centers without a PET\/CT or a 68Ga generator. Because of wider availability, a lower cost, and a longer decay, compared with respect to peptides labeled with 68Ga, it could be also proposed, in a theranostic context, for a dosimetry evaluation of patients undergoing Peptide Receptor Radionuclide Therapy (PRRT), and for non-oncologic indications of radiolabelled SSA. In this direction, and for a more rigorous cost\/effective evaluation, more precisely individuating its clinical role, further studies are needed.<\/jats:p><\/jats:sec>","DOI":"10.2174\/1874471012666190301122524","type":"journal-article","created":{"date-parts":[[2019,3,4]],"date-time":"2019-03-04T12:03:15Z","timestamp":1551700995000},"page":"156-170","update-policy":"http:\/\/dx.doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Gamma Emitters in Pancreatic Endocrine Tumors Imaging in the PET Era: Is there a Clinical Space for 99mTc-peptides?"],"prefix":"10.2174","volume":"12","author":[{"given":"Vittorio","family":"Briganti","sequence":"first","affiliation":[{"name":"Nuclear Medicine Unit - Azienda Ospedaliero Universitaria Careggi Firenze, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincenzo","family":"Cuccurullo","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Unit, Department of Clinical and Experimental Medicine \"F.Magrassi, A.Lanzara\" \u2013 Universit\u00e0 della Campania \"Luigi Vanvitelli\", Napoli, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe Danilo","family":"Di Stasio","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Unit, Department of Clinical and Experimental Medicine \"F.Magrassi, A.Lanzara\" \u2013 Universit\u00e0 della Campania \"Luigi Vanvitelli\", Napoli, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigi","family":"Mansi","sequence":"additional","affiliation":[{"name":"Health and Development Section, Interuniversitary Research Center for Sustainable Development, Napoli-Roma, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1677\/erc.0.0100427","volume":"10","author":"Rindi G.","year":"2003","unstructured":"Rindi G, Bordi C. Endocr Relat Cancer, Highlights of the biology of endocrine tumours of the gut and pancreas.,, 2003, 10,, 427-436,","journal-title":"Endocr Relat Cancer"},{"key":"ref=2","doi-asserted-by":"crossref","first-page":"5377","DOI":"10.3748\/wjg.14.5377","volume":"14","author":"Massironi S.","year":"2008","unstructured":"Massironi S, Sciola V, Peracchi M, Ciafardini C, Spampatti MP, Conte D. World J Gastroenterol, Neuroendocrine tumors of the gastro-entero-pancreatic system.,, 2008, 14,, 5377-5384,","journal-title":"World J Gastroenterol"},{"key":"ref=3","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1634\/theoncologist.2008-0259","volume":"14","author":"Ehehalt F.","year":"2009","unstructured":"Ehehalt F, Saeger HD, Schmidt CM, Grutzmann R. Oncologist, Neuroendocrine tumors of the pancreas.,, 2009, 14,, 456-467,","journal-title":"Oncologist"},{"key":"ref=4","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1200\/JCO.2007.15.4377","volume":"26","author":"Yao J.C.","year":"2008","unstructured":"Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla EK, Fleming JB, Vauthey JN, Rashid A, Evans DB. J Clin Oncol, One hundred years after \u201ccarcinoid\u201d: Epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States.,, 2008, 26,, 3063-3072,","journal-title":"J Clin Oncol"},{"key":"ref=5","first-page":"41","volume":"36","author":"Cuccurullo V.","year":"2011","unstructured":"Cuccurullo V, Cascini GL, Tamburrini O, Mansi L, Rotondo A. Minerva Endocrinol, Less frequent requests for In-111 pentreotide and its brothers of endocrinological interest.,, 2011, 36,, 41-52,","journal-title":"Minerva Endocrinol"},{"key":"ref=6","doi-asserted-by":"crossref","first-page":"309","DOI":"10.2214\/AJR.12.8627","volume":"199","author":"Raman S.P.","year":"2012","unstructured":"Raman SP, Hruban RH, Cameron JL, Wolfgang CL, Fishman EK. AJR Am J Roent, Pancreatic imaging mimics: part 2, pancreatic neuroendocrine tumors and their mimics.,, 2012, 199,, 309-318,","journal-title":"AJR Am J Roent"},{"key":"ref=7","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1007\/BF00181765","volume":"20","author":"Krenning E.P.","year":"1993","unstructured":"Krenning EP, Kwekkeboom DJ, Bakker WH, Breeman WA, Kooij PP, Oei HY. Eur J Nucl Med, Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients.,, 1993, 20,, 716-731,","journal-title":"Eur J Nucl Med"},{"key":"ref=8","first-page":"42","volume":"44","author":"Chiti A.","year":"2000","unstructured":"Chiti A, Briganti V, Fanti S, Monetti N, Masi R, Bombardieri E. Q J Nucl Med, Results and potential of somatostatin receptor imaging in gastroenteropancreatic tract tumours.,, 2000, 44,, 42-49,","journal-title":"Q J Nucl Med"},{"key":"ref=9","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s002590050197","volume":"25","author":"Adams S.","year":"1998","unstructured":"Adams S, Baum R, Rink T, Schumm-Drager PM, Usadel KH, Hor G. Eur J Nucl Med, Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours.,, 1998, 25,, 79-83,","journal-title":"Eur J Nucl Med"},{"key":"ref=10","first-page":"16","volume":"54","author":"Ambrosini V.","year":"2010","unstructured":"Ambrosini V, Tomassetti P, Franchi R, Fanti S. Q J Nucl Med, Imaging of NETs with PET radiopharmaceuticals.,, 2010, 54,, 16-23,","journal-title":"Q J Nucl Med"},{"key":"ref=11","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1177\/0284185113496679","volume":"55","author":"Yang J.","year":"2014","unstructured":"Yang J, Kan Y, Ge BH, Yuan L, Li C, Zhao W. Acta Radiol, Diagnostic role of Gallium-68 DOTATOC and Gallium-68 DOTATATE PET in patients with neuroendocrine tumors: A meta-analysis.,, 2014, 55,, 389-398,","journal-title":"Acta Radiol"},{"key":"ref=12","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s00259-014-2943-z","volume":"42","author":"Imperiale A.","year":"2015","unstructured":"Imperiale A, Sebag F, Vix M, Castinetti F, Kessler L, Moreau F. Eur J Nucl Med, 18F-FDOPA PET\/CT imaging of insulinoma revisited.,, 2015, 42,, 409-418,","journal-title":"Eur J Nucl Med"},{"key":"ref=13","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/BF02996303","volume":"16","author":"Shih W.J.","year":"2002","unstructured":"Shih WJ, Hirschowitz E, Bensadoun E, Woodring J, Ryo Yu, Kraman S. Ann Nucl Med, Biodistribution on Tc-99m labeled somatostatin receptor-binding peptide (Depreotide, NeoTec) planar and SPECT studies.,, 2002, 16,, 213-219,","journal-title":"Ann Nucl Med"},{"key":"ref=14","first-page":"537","volume":"17","author":"Artiko V.","year":"2012","unstructured":"Artiko V, Sobic-Saranovic D, Pavlovic S, Petrovic M, Zuvela M, Antic A, Matic S, Odalovic S, Petrovic N, Milovanovic A, Obradovic V. J BUON, The clinical value of scintigraphy of neuroendocrine tumors using (99m)Tc-HYNIC-TOC.,, 2012, 17,, 537-542,","journal-title":"J BUON"},{"key":"ref=15","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.bpg.2005.05.008","volume":"19","author":"Grant C.S.","year":"2005","unstructured":"Grant CS. Best Pract Res Clin Gastroenterol, Insulinoma.,, 2005, 19,, 783-798,","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"ref=16","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/jso.21773","volume":"103","author":"Zhao Y.P.","year":"2011","unstructured":"Zhao YP, Zhan HX, Zhang TP, Cong L, Dai MH, Liao Q. J Surg Oncol, Surgical management of patients with insulinomas: Result of 292 cases in a single institution.,, 2011, 103,, 169-174,","journal-title":"J Surg Oncol"},{"key":"ref=17","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1210\/jc.2008-1986","volume":"94","author":"Guettier J.M.","year":"2009","unstructured":"Guettier JM. J Clin Endocrinol Metab, 1.; Kam, A.; Chang, R.; Skarulis, M.C.; Cochran, C.; Alexander, H.R.; Libutti, S.K.; Pingpank, J.F.; Gorden, P. Localization of insulinomas to regions of the pancreas by intraarterial calcium stimulation: The NIH experience.,, 2009, 94,, 1074-1080,","journal-title":"J Clin Endocrinol Metab"},{"key":"ref=18","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1007\/s12020-007-0045-4","volume":"31","author":"Sotoudehmanesh R.","year":"2007","unstructured":"Sotoudehmanesh R, Hedayat A, Shirazian N, Shahraeeni S, Ainechi S, Zeinali F. Endocrine, Endoscopic ultrasonography (EUS) in the localization of insulinoma.,, 2007, 31,, 238-241,","journal-title":"Endocrine"},{"key":"ref=19","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1007\/s00268-006-0106-5","volume":"31","author":"Wong M.","year":"2007","unstructured":"Wong M, Isa SH, Zahiah M, Azmi KN. World J Surg, Intraoperative ultrasound with palpation is still superior to intra-arterial calcium stimulation test in localising insulinoma.,, 2007, 31,, 586-592,","journal-title":"World J Surg"},{"key":"ref=20","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1007\/s00259-016-3331-7","volume":"43","author":"Prasad V.","year":"2016","unstructured":"Prasad V, Sainz-Esteban A, Arsenic R, Pl\u00f6ckinger U, Denecke T, Pape UF, Pascher A, K\u00fchnen P, Pavel M, Blankenstein O. Eur J Nucl Med, Role of (68)Ga somatostatin receptor PET\/CT in the detection of endogenous hyperinsulinaemic focus: An explorative study.,, 2016, 43,, 1593-1600,","journal-title":"Eur J Nucl Med"},{"key":"ref=21","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1007\/s00259-007-0476-4","volume":"34","author":"Hubalewska-Dydejczyk A.","year":"2007","unstructured":"Hubalewska-Dydejczyk A, Kulig J, Szybinski P, Mikolajczak R, Pach D, Sowa-Staszczak A. Eur J Nucl Med, Radio-guided surgery with the use of [99mTc-EDDA\/HYNIC]octreotate in intra-operative detection of neuroendocrine tumours of the gastrointestinal tract.,, 2007, 34,, 1545-1555,","journal-title":"Eur J Nucl Med"},{"key":"ref=22","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1002\/cncr.21179","volume":"104","author":"Hirshberg B.","year":"2005","unstructured":"Hirshberg B. Cancer, 1.; Cochran, C.; Skarulis, M.C.; Libutti, S.K.; Alexander, H.R.; Wood, B.J.; Chang, R.; Kleiner, D.E.; Gorden, P. Malignant insulinoma: Spectrum of unusual clinical features.,, 2005, 104,, 264-272,","journal-title":"Cancer"},{"key":"ref=23","doi-asserted-by":"crossref","first-page":"3157","DOI":"10.1210\/jc.2009-0788","volume":"94","author":"Bourcier M.E.","year":"2009","unstructured":"Bourcier ME, Sherrod A, DiGuardo M, Vinik AI. J Clin Endocrinol Metab, Successful control of intractable hypoglycemia using rapamycin in an 86-year-old man with a pancreatic insulin-secreting islet cell tumor and metastases.,, 2009, 94,, 3157-3162,","journal-title":"J Clin Endocrinol Metab"},{"key":"ref=24","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1530\/EJE-09-1010","volume":"162","author":"Ong G.S.","year":"2010","unstructured":"Ong GS, Henley DE, Hurley D, Turner JH, Claringbold PG, Fegan PG. Eur J Endocrinol, Therapies for the medical management of persistent hypoglycaemia in two cases of inoperable malignant insulinoma.,, 2010, 162,, 1001-1008,","journal-title":"Eur J Endocrinol"},{"key":"ref=25","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1007\/s11894-004-0067-5","volume":"6","author":"Gibril F.","year":"2004","unstructured":"Gibril F, Jensen RT. Curr Gastroenterol Rep, Zollinger-Ellison syndrome revisited, diagnosis, biologic markers, associated inherited disorders, and acid hypersecretion.,, 2004, 6,, 454-463,","journal-title":"Curr Gastroenterol Rep"},{"key":"ref=26","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/0002-9610(84)90029-1","volume":"147","author":"Stabile B.E.","year":"1984","unstructured":"Stabile BE, Morrow DJ, Passaro E. Am J Surg, Jr. The gastrinoma triangle: operative implications.,, 1984, 147,, 25-31,","journal-title":"Am J Surg"},{"key":"ref=27","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/01.md.0000236956.74128.76","volume":"85","author":"Berna M.J.","year":"2006","unstructured":"Berna MJ, Hoffmann KM, Serrano J, Gibril F, Jensen RT. Medicine, Serum gastrin in Zollinger-Ellison syndrome: I. Prospective study of fasting serum gastrin in 309 patients from the National Institutes of Health and comparison with 2229 cases from the literature.,, 2006, 85,, 295-330,","journal-title":"Medicine"},{"key":"ref=28","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s00261-004-0299-8","volume":"30","author":"Pfannenberg A.C.","year":"2005","unstructured":"Pfannenberg AC, Burkart C, Krober SM, Eschmann SM, Horger MS, Claussen CD. Abdom Imaging, Dual-phase multidetector thin-section CT in detecting duodenal gastrinoma.,, 2005, 30,, 543-547,","journal-title":"Abdom Imaging"},{"key":"ref=29","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/BF02805221","volume":"19","author":"Prinz R.A.","year":"1996","unstructured":"Prinz RA. Int J of pancreatology, Localization of gastrinomas.,, 1996, 19,, 79-91,","journal-title":"Int J of pancreatology"},{"key":"ref=30","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/S0016-5085(00)70139-9","volume":"118","author":"Lew E.A.","year":"2000","unstructured":"Lew EA, Pisegna JR, Starr JA, Soffer EF, Forsmark C, Modlin IM, Walsh JH, Beg M, Bochenek W, Metz DC. Gastroenterology, Intravenous pantoprazole rapidly controls gastric acid hypersecretion in patients with Zollinger-Ellison syndrome.,, 2000, 118,, 696-704,","journal-title":"Gastroenterology"},{"key":"ref=31","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0960-7404(03)00035-5","volume":"12","author":"Norton J.A.","year":"2003","unstructured":"Norton JA, Jensen RT. Surg Oncol, Current surgical management of Zollinger-Ellison syndrome (ZES) in patients without multiple endocrine neoplasia-type 1 (MEN1).,, 2003, 12,, 145-151,","journal-title":"Surg Oncol"},{"key":"ref=32","first-page":"282","volume":"14","author":"Mekhjian H.S.","year":"1987","unstructured":"Mekhjian HS, O\u2019Dorisio TM. Semin Oncol, VIPoma syndrome.,, 1987, 14,, 282-291,","journal-title":"Semin Oncol"},{"key":"ref=33","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/S0950-3528(96)90018-4","volume":"10","author":"Park S.K.","year":"1996","unstructured":"Park SK, O\u2019Dorisio MS, O\u2019Dorisio TM. Baillieres Clin Gastroenterol, Vasoactive intestinal polypeptide-secreting tumours: Biology and therapy.,, 1996, 10,, 673-696,","journal-title":"Baillieres Clin Gastroenterol"},{"key":"ref=34","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/0016-5085(91)90588-C","volume":"100","author":"Koch T.R.","year":"1991","unstructured":"Koch TR, Michener SR, Go VL. Gastroenterology, Plasma vasoactive intestinal polypeptide concentration determination in patients with diarrhea.,, 1991, 100,, 99-106,","journal-title":"Gastroenterology"},{"key":"ref=35","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1007\/s11605-007-0177-0","volume":"12","author":"Ghaferi A.A.","year":"2008","unstructured":"Ghaferi AA, Chojnacki KA, Long WD, Cameron JL, Yeo CJ. J Gastrointest Surg, Pancreatic VIPomas: Subject review and one institutional experience.,, 2008, 12,, 382-393,","journal-title":"J Gastrointest Surg"},{"key":"ref=36","doi-asserted-by":"crossref","first-page":"36","DOI":"10.2174\/1874471011306010006","volume":"6","author":"Cascini G.L.","year":"2013","unstructured":"Cascini GL, Cuccurullo V, Tamburrini O, Rotondo A, Mansi L. Curr Radiopharm, Peptide imaging with somatostatin analogues: more than cancer probes.,, 2013, 6,, 36-40,","journal-title":"Curr Radiopharm"},{"key":"ref=37","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1007\/s12032-007-0011-2","volume":"24","author":"Kindmark H.","year":"2007","unstructured":"Kindmark H, Sundin A, Granberg D, Dunder K, Skogseid B, Janson ET. Med Oncol, Endocrine pancreatic tumors with glucagon hypersecretion: A retrospective study of 23 cases during 20 years.,, 2007, 24,, 330-337,","journal-title":"Med Oncol"},{"key":"ref=38","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1097\/00005792-199603000-00002","volume":"75","author":"Wermers R.A.","year":"1996","unstructured":"Wermers RA, Fatourechi V, Wynne AG, Kvols LK, Lloyd RV. Medicine, The glucagonoma syndrome. Clinical and pathologic features in 21 patients.,, 1996, 75,, 53-63,","journal-title":"Medicine"},{"key":"ref=39","doi-asserted-by":"crossref","first-page":"28S","DOI":"10.1007\/BF01536043","volume":"34","author":"Maton P.N.","year":"1989","unstructured":"Maton PN, Gardner JD, Jensen RT. Dig Dis Sci, Use of long-acting somatostatin analog SMS 201-995 in patients with pancreatic islet cell tumors.,, 1989, 34,, 28S-39S,","journal-title":"Dig Dis Sci"},{"key":"ref=40","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1056\/NEJM198606263142606","volume":"314","author":"Boden G.","year":"1986","unstructured":"Boden G, Ryan IG, Eisenschmid BL, Shelmet JJ, Owen OE. N Engl J Med, Treatment of inoperable glucagonoma with the long-acting somatostatin analogue SMS 201-995.,, 1986, 314,, 1686-1689,","journal-title":"N Engl J Med"},{"key":"ref=41","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1007\/s00268-008-9499-7","volume":"32","author":"Kuo S.C.","year":"2008","unstructured":"Kuo SC, Gananadha S, Scarlett CJ, Gill A, Smith RC. World J Surg, Sporadic pancreatic polypeptide secreting tumors (PPomas) of the pancreas.,, 2008, 32,, 1815-1822,","journal-title":"World J Surg"},{"key":"ref=42","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1067\/msy.2001.118367","volume":"130","author":"Solorzano C.C.","year":"2001","unstructured":"Solorzano CC, Lee JE, Pisters PW, Vauthey JN, Ayers GD, Jean ME. Surgery, Nonfunctioning islet cell carcinoma of the pancreas: Survival results in a contemporary series of 163 patients.,, 2001, 130,, 1078-1085,","journal-title":"Surgery"},{"key":"ref=43","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1002\/jso.20178","volume":"89","author":"Kouvaraki M.A.","year":"2005","unstructured":"Kouvaraki MA, Solorzano CC, Shapiro SE, Yao JC, Perrier ND, Lee JE. J Surg Oncol, Surgical treatment of non-functioning pancreatic islet cell tumors.,, 2005, 89,, 170-185,","journal-title":"J Surg Oncol"},{"key":"ref=44","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1055\/s-2005-870139","volume":"37","author":"Agarwal S.K.","year":"2005","unstructured":"Agarwal SK, Kennedy PA, Scacheri PC, Novotny EA, Hickman AB, Cerrato A. Horm Metab Res, Menin molecular interactions: insights into normal functions and tumorigenesis.,, 2005, 37,, 369-374,","journal-title":"Horm Metab Res"},{"key":"ref=45","first-page":"397","volume":"54","author":"Marx S.J.","year":"1999","unstructured":"Marx SJ, Agarwal SK, Kester MB, Heppner C, Kim YS, Skarulis MC. Recent Prog Horm Res, Multiple endocrine neoplasia type 1: Clinical and genetic features of the hereditary endocrine neoplasias.,, 1999, 54,, 397-438,","journal-title":"Recent Prog Horm Res"},{"key":"ref=46","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1196\/annals.1294.020","volume":"1014","author":"Agarwal S.K.","year":"2004","unstructured":"Agarwal SK, Lee Burns A, Sukhodolets KE, Kennedy PA, Obungu VH, Hickman AB. Ann N Y Acad Sci, Molecular pathology of the MEN1 gene.,, 2004, 1014,, 189-198,","journal-title":"Ann N Y Acad Sci"},{"key":"ref=47","doi-asserted-by":"crossref","first-page":"5658","DOI":"10.1210\/jcem.86.12.8070","volume":"86","author":"Brandi M.L.","year":"2001","unstructured":"Brandi ML, Gagel RF, Angeli A, Bilezikian JP, Beck-Peccoz P, Bordi C, Conte-Devolx B, Falchetti A, Gheri RG, Libroia A, Lips CJ, Lombardi G, Mannelli M, Pacini F, Ponder BA, Raue F, Skogseid B, Tamburrano G, Thakker RV, Thompson NW, Tomassetti P, Tonelli F, Wells SA. J Clin Endocrinol Metab, Jr., Marx, S.J. Guidelines for diagnosis and therapy of MEN type 1 and type 2.,, 2001, 86,, 5658-5671,","journal-title":"J Clin Endocrinol Metab"},{"key":"ref=48","doi-asserted-by":"crossref","first-page":"2990","DOI":"10.1210\/jc.2012-1230","volume":"97","author":"Thakker R.","year":"2012","unstructured":"Thakker R. J Clin Endocrinol Metab, V1.; Newey, P.J.; Walls, G.V.; Bilezikian, J.; Dralle, H.; Ebeling, P.R.; Melmed, S.; Sakurai, A.; Tonelli, F.; Brandi, M.L. Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1).,, 2012, 97,, 2990-3011,","journal-title":"J Clin Endocrinol Metab"},{"key":"ref=49","doi-asserted-by":"crossref","first-page":"33","DOI":"10.4158\/EP10376.RA","volume":"17","author":"Tonelli F.","year":"2011","unstructured":"Tonelli F, Giudici F, Fratini G, Brandi ML. Endocr Pract, Pancreatic endocrine tumors in multiple endocrine neoplasia type 1 syndrome: review of literature.,, 2011, 17,, 33-40,","journal-title":"Endocr Pract"},{"key":"ref=50","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/ejhg.2010.175","volume":"19","author":"Maher E.R.","year":"2011","unstructured":"Maher ER, Neumann HP, Richard S. Eur J Hum Genet, von Hippel-Lindau disease: A clinical and scientific review.,, 2011, 19,, 617-623,","journal-title":"Eur J Hum Genet"},{"key":"ref=51","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrc885","volume":"2","author":"Kaelin W.G.","year":"2002","unstructured":"Kaelin WG. Nat Rev Cancer, Jr. Molecular basis of the VHL hereditary cancer syndrome.,, 2002, 2,, 673-682,","journal-title":"Nat Rev Cancer"},{"key":"ref=52","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s10147-004-0415-3","volume":"9","author":"Shuin T.","year":"2004","unstructured":"Shuin T, Yamazaki I, Tamura K, Kamada M, Ashida S. Int J Clin Oncol, Recent advances in ideas on the molecular pathology and clinical aspects of Von Hippel-Lindau disease.,, 2004, 9,, 283-287,","journal-title":"Int J Clin Oncol"},{"key":"ref=53","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1097\/MPA.0b013e3181b2bb03","volume":"38","author":"Zhou C.","year":"2009","unstructured":"Zhou C, Dhall D, Nissen NN, Chen CR, Yu R. Pancreas, Homozygous P86S mutation of the human glucagon receptor is associated with hyperglucagonemia, alpha cell hyperplasia, and islet cell tumor.,, 2009, 38,, 941-946,","journal-title":"Pancreas"},{"key":"ref=54","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.endonu.2011.04.002","volume":"58","author":"Yu R.","year":"2011","unstructured":"Yu R, Wawrowsky K, Zhou C. Endocrinol Nutr, A natural inactivating mutant of human glucagon receptor exhibits multiple abnormalities in processing and signaling.,, 2011, 58,, 258-266,","journal-title":"Endocrinol Nutr"},{"key":"ref=55","doi-asserted-by":"crossref","first-page":"e23397","DOI":"10.1371\/journal.pone.0023397","volume":"6","author":"Yu R.","year":"2011","unstructured":"Yu R, Dhall D, Nissen NN, Zhou C, Ren SG. PLoS One, Pancreatic neuroendocrine tumors in glucagon receptor-deficient mice.,, 2011, 6,, e23397-,","journal-title":"PLoS One"},{"key":"ref=56","first-page":"1919","volume":"38","author":"Stabin M.G.","year":"1997","unstructured":"Stabin MG, Kooij PP, Bakker WH, Inoue T, Endo K, Coveney J. J Nucl Med, Radiation dosimetry for indium-111-pentetreotide.,, 1997, 38,, 1919-1922,","journal-title":"J Nucl Med"},{"key":"ref=57","doi-asserted-by":"crossref","first-page":"74","DOI":"10.2174\/1874471010666170323115136","volume":"10","author":"Cuccurullo V.","year":"2017","unstructured":"Cuccurullo V, Prisco MR, Di Stasio GD, Mansi L. Curr Radiopharm, Nuclear Medicine in Patients with NET: Radiolabeled Somatostatin Analogues and their Brothers.,, 2017, 10,, 74-84,","journal-title":"Curr Radiopharm"},{"key":"ref=58","first-page":"509","volume":"27","author":"Cuccurullo V.","year":"2017","unstructured":"Cuccurullo V, Di Stasio GD, Prisco MR, Mansi L. Indian J Radiol Imaging, Is there a clinical usefulness for radiolabeled somatostatin analogues beyond the consolidated role in NETs?,, 2017, 27,, 509-516,","journal-title":"Indian J Radiol Imaging"},{"key":"ref=59","doi-asserted-by":"crossref","first-page":"49","DOI":"10.5603\/NMR.2017.0003","volume":"20","author":"Cuccurullo V.","year":"2017","unstructured":"Cuccurullo V, Di Stasio GD, Mansi L. Nucl Med Rev Cent East Eur, Radioguided surgery with radiolabeled somatostatin analogs: Not only in GEP-NETs.,, 2017, 20,, 49-56,","journal-title":"Nucl Med Rev Cent East Eur"},{"key":"ref=60","first-page":"708","volume":"44","author":"Gabriel M.","year":"2003","unstructured":"Gabriel M, Decristoforo C, Donnemiller E, Ulmer H. J Nucl Med, Watfah, Rychlinski C.; Mather, S.J. An intrapatient comparison of 99mTc-EDDA\/HYNIC-TOC with 111In-DTPA-octreotide for diagnosis of somatostatin receptor-expressing tumors.,, 2003, 44,, 708-716,","journal-title":"J Nucl Med"},{"key":"ref=61","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1097\/RLU.0000000000001877","volume":"42","author":"Kunikowska J.","year":"2017","unstructured":"Kunikowska J, Lewington V, Krolicki L. Clin Nucl Med, Optimizing somatostatin receptor imaging in patients with neuroendocrine tumors: The impact of 99mTc-Hynictoc SPECT\/SPECT\/CT Versus 68Ga-DOTATATE PET\/CT upon clinical management.,, 2017, 42,, 905-911,","journal-title":"Clin Nucl Med"},{"key":"ref=62","doi-asserted-by":"crossref","first-page":"508","DOI":"10.2967\/jnumed.106.035667","volume":"48","author":"Gabriel M.","year":"2007","unstructured":"Gabriel M, Decristoforo C, Kendler D, Dobrozemsky G, Heute D, Uprimny C. J Nucl Med, 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT.,, 2007, 48,, 508-518,","journal-title":"J Nucl Med"},{"key":"ref=63","first-page":"367","volume":"37","author":"Cuccurullo V.","year":"2012","unstructured":"Cuccurullo V, Faggiano A, Scialpi M, Cascini GL, Piunno A, Catalano O, Colao A, Mansi L. Minerva Endocrinol, Questions and answers: what can be said by diagnostic imaging in neuroendocrine tumors?,, 2012, 37,, 367-377,","journal-title":"Minerva Endocrinol"},{"key":"ref=64","doi-asserted-by":"crossref","first-page":"88","DOI":"10.5603\/NMR.2016.0018","volume":"19","author":"Madrzak D.","year":"2016","unstructured":"Madrzak D, Mikolajczak R, Kaminski G. Nucl Med Rev Cent East Eur, Influence of PET\/CT 68Ga somatostatin receptor imaging on proceeding with patients, who were previously diagnosed with 99mTc-EDDA\/HYNIC-TOC SPECT.,, 2016, 19,, 88-92,","journal-title":"Nucl Med Rev Cent East Eur"},{"key":"ref=65","first-page":"2385","volume":"3","author":"Briganti V.","year":"1997","unstructured":"Briganti V, Sestini R, Orlando C, Bernini G, La Cava G, Tamburini A, Raggi CC, Serio M, Maggi M. Clin Cancer Res, Imaging of somatostatin receptors by indium-111-pentetreotide correlates with quantitative determination of somatostatin receptor type 2 gene expression in neuroblastoma tumors.,, 1997, 3,, 2385-2391,","journal-title":"Clin Cancer Res"},{"key":"ref=66","first-page":"419","volume":"8","author":"Casini Raggi C.","year":"2002","unstructured":"Casini Raggi C, Calabr\u00f2 A, Renzi D, Briganti V, Cianchi F, Messerini L, Valanzano R, Cameron Smith M, Cortesini C, Tonelli F, Serio M, Maggi M, Orlando C. Clin Cancer Res, Quantitative evaluation of somatostatin receptor subtype 2 expression in sporadic colorectal tumor and in the corresponding normal mucosa.,, 2002, 8,, 419-427,","journal-title":"Clin Cancer Res"},{"key":"ref=67","doi-asserted-by":"crossref","first-page":"e141","DOI":"10.1097\/RLU.0b013e31823926e5","volume":"37","author":"Ezziddin S.","year":"2012","unstructured":"Ezziddin S, Lohmar J, Yong-Hing CJ, Sabet A, Ahmadzadehfar H, Kukuk G. Clin Nucl Med, Does the pretherapeutic tumor SUV in 68Ga DOTATOC PET predict the absorbed dose of 177Lu octreotate?,, 2012, 37,, e141-e147,","journal-title":"Clin Nucl Med"},{"key":"ref=68","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1007\/s00259-012-2330-6","volume":"40","author":"Bodei L.","year":"2013","unstructured":"Bodei L, Mueller-Brand J, Baum RP, Pavel ME, H\u00f6rsch D, O\u2019Dorisio MS, O\u2019Dorisio TM, Howe JR, Cremonesi M, Kwekkeboom DJ, Zaknun JJ. Eur J Nucl Med, The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours.,, 2013, 40,, 800-816,","journal-title":"Eur J Nucl Med"},{"key":"ref=69","first-page":"265","volume":"50","author":"Bakker W.H.","year":"2006","unstructured":"Bakker WH, Breeman WA, Kwekkeboom DJ, De Jong LC, Krenning EP. Q J Nucl Med Mol Imaging, Practical aspects of peptide receptor radionuclide therapy with [177Lu][DOTA0, Tyr3]octreotate.,, 2006, 50,, 265-271,","journal-title":"Q J Nucl Med Mol Imaging"},{"key":"ref=70","author":"Cuccurullo V.","year":"2019","unstructured":"Cuccurullo V, Di Stasio GD, Mansi L. Curr Radiopharm, Physiopathological premises to Nuclear Medicine Imaging of pancreatic neuroendocrine tumours.,, 2019, 50,, 265-,In Press","journal-title":"Curr Radiopharm"}],"container-title":["Current Radiopharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/170355","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T23:36:02Z","timestamp":1663025762000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/170355\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,16]]},"references-count":70,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,7,16]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1874471012666190301122524","relation":{},"ISSN":["1874-4710"],"issn-type":[{"value":"1874-4710","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7,16]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2018-04-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-06-15","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-10-19","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-07-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}